About Ampersand
Ampersand is a company based in Boston (United States) founded in 2020 by Raffi Afeyan and Noubar Afeyan. It operates as a HealthTech. Ampersand has raised $65 million across 1 funding round from investors including Lilly and Flagship Pioneering. The company has 22 employees as of December 31, 2022. Ampersand has completed 1 acquisition, including AbCheck. Ampersand offers products and services including AND-Body Therapeutics. Ampersand operates in a competitive market with competitors including DNAnexus, Cytel, Metagenomi, Octant and Kinomica, among others.
- Headquarter Boston, United States
- Employees 22 as on 31 Dec, 2022
- Founders Raffi Afeyan, Noubar Afeyan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ampersand Biomedicines
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ampersand
Ampersand offers a comprehensive portfolio of products and services, including AND-Body Therapeutics.
Programmable medicines are designed for disease-specific precision targeting.
People of Ampersand
Unlock access to complete
Funding Insights of Ampersand
Ampersand has successfully raised a total of $65M through 1 strategic funding round. The most recent funding activity was a Series B round of $65 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ampersand
Ampersand has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked | |
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Locked | Locked | Locked |
Investor details for Ampersand
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ampersand
Ampersand has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AbCheck.
Investment portfolio details for Ampersand
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of human therapeutic antibodies
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Ampersand
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ampersand
Detailed financials for Ampersand
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ampersand Comparisons
Peer comparison for Ampersand
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ampersand
Ampersand operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Cytel, Metagenomi, Octant and Kinomica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| Locked | Locked | Locked |
Human cell interaction platform is provided for drug discovery.
|
|
| Locked | Locked | Locked |
Bioinformatics platform for precision medicine development is offered.
|
Detailed competitors of Ampersand
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ampersand
Complete news archive for Ampersand
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ampersand
Ampersand was founded in 2020 and raised its 1st funding round 5 years after it was founded.
Ampersand is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Jason Gardner is the current CEO of Ampersand.
Ampersand is a funded company, having raised a total of $65M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Ampersand is 22.
Ampersand Biomedicines is engaged in the development of next-generation modular medicines through its proprietary Address, Navigate, Determine (AND) Platform. These medicines, known as AND-Body Therapeutics, are designed to act precisely at the site of disease, avoiding healthy tissue to minimize side effects. The company operates in the biotechnology sector, addressing challenges in drug development by combining localizing elements and actuators for disease modification. Solutions are enabled by a unique Address Map to identify optimal targets for organs, cells, and diseases, ensuring safer and more effective treatments.
Ampersand's top competitors include DNAnexus, Cytel and Relation Therapeutics.
Ampersand offers AND-Body Therapeutics.
Ampersand has made 1 acquisition, including AbCheck.
Ampersand has 2 investors. Key investors include Lilly, and Flagship Pioneering.